First-in-human clinical trial of genetically engineered B cells: Application to the treatment of mucopolysaccharidosis type I
Funding will enable the Company to support expanded development of its lead asset, ISP-001, for the treatment of mucopolysaccharidosis type 1 San Francisco, CA., March 30, 2026 — Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, announced today that the California…
